Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Clinical Neurology
Reference6 articles.
1. Aartsma-Rus, A. & Krieg, A. M. FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid. Ther. 27, 1–3 (2017).
2. Charleston, J. S. et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology
https://doi.org/10.1212/WNL.0000000000005680
(2018).
3. Schnell, F. et al. Development of a validated Western blot method for quantification of human dystrophin protein used in phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) (P5.105). Neurology 88, S16 (2017).
4. Anthony, K. et al. Dystrophin quantification: biological and translational research implications. Neurology 83, 2062–2069 (2014).
5. Arechavala-Gomeza, V. et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul. Disord. 20, 295–301 (2010).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献